New research brings awareness to potential heart problems linked to non-stimulant prescription drugs for the condition. In a ...

The Food and Drug Administration (FDA) approved an extended-release version of guanfacine to treat attention deficit hyperactivity disorder (ADHD) in children and teenagers ages 6 to 17 years old.